Wednesday, July 8, 2026

Patent intelligence · US

US 10472381

Sialic acid derivatives

granted A61KA61K31/7028A61PA61P29/00
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 13
Applicant portfolio 11
Patent details — US 10472381
Jurisdiction
US
Status
granted
Grant date
Nov 12, 2019
Expiration
Nov 7, 2039
Applicant
Reinhard Brossmer
Claims
17
CPC classes
A61K, A61K31/7028, A61P, A61P29/00
View on Google Patents ↗

Quick answer

US 10472381 (Sialic acid derivatives) is held by Reinhard Brossmer. Status: granted. Granted Nov 12, 2019. Expires Nov 7, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
Reinhard Brossmer
Grant date
Expiration
Claims
17
CPC classes
A61K, A61K31/7028, A61P, A61P29/00, A61P31/04, A61P37/08

More from Reinhard Brossmer

Related pharmaceutical patents in our USPTO index.

  1. US 12390512

    Depolymerase capable of degrading extracellular polymeric substances of Klebsiella pneumoniae

    SHANGHAI REINOVAX BIOLOGICS CO., LTD · Expires Aug 14, 2045

    granted
  2. US 11033623

    Magnetic stem cell therapy for lesions

    GREINER BIO-ONE NORTH AMERICA, INC. · Expires Jun 10, 2041

    granted
  3. US 10265396

    Magnetic extracellular matrix

    GREINER BIO-ONE NORTH AMERICA, INC. · Expires Apr 18, 2039

    granted
  4. US 9539228

    Composition containing lysine as a nutritional supplement or treatment in the case of herpes

    Reiner Rittinghausen · Expires Jan 5, 2037

    granted
  5. US 8309071

    Foamy viral envelope genes

    Vectoria Forschungsforderungs Verein E.V. · Expires Nov 8, 2032

    granted
  6. US 8293803

    Retinoid compounds and their use

    Reinnervate Limited · Expires Oct 18, 2032

    granted
  7. US 8268792

    Use of an active ingredient combination that contains hydroxystilbene for preventing and/or treating diseases

    Reinhard Rettenberger · Expires Sep 13, 2032

    granted

Frequently asked questions

What is US patent 10472381?

US 10472381 (Sialic acid derivatives) is held by Reinhard Brossmer. Status: granted. Granted Nov 12, 2019. Expires Nov 7, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10472381?

Reinhard Brossmer is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 11 pharmaceutical patents for this assignee.

When does US 10472381 expire?

Our index shows an expiration date of Nov 7, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.